Respiratory syncytial virus leads to 177,000 hospitalizations, 14,000 deaths in U.S. annually
Pfizer said on Monday its respiratory syncytial virus vaccine Abrysvo generated a strong immune response in a late-stage study of four groups of adults aged 18 and older with a compromised immune system.
A single 120 microgram dose of the vaccine generated strong neutralizing antibodies against both subtypes of RSV, called RSV-A and RSV-B, across all groups in the study, Pfizer said. Abrysvo was well-tolerated in the study and showed a safety profile consistent with findings from other studies of the vaccine, it added.The study tested two doses of Abrysvo in 203 adults across four groups – those with a type of lung cancer, end-stage kidney disease, autoimmune inflammatory disorder, and solid organ transplant recipients – all of whom have compromised immunity and are at risk of developing severe RSV-associated disease.
Pfizer’s vaccine is currently approved for people aged 60 and older and for use in women during the middle of the third trimester of pregnancy to protect their babies. RSV typically causes cold-like symptoms but is also a leading cause of pneumonia in toddlers and older adults, leading to 177,000 hospitalizations and 14,000 deaths in the United States annually.
Canada News Breaking News Video Canadian Breaking News Breaking News Globe And Mail Breaking News Globe And Mail Canada News Photos World News Local News National News Us News Foreign News Sports News Arts News Life News Lifestyle Canada Traffic Canada Weather Trudeau Government Federal Government Canada Sports Canada Sports News Politics Politics News Political News Political Opinion Environment Economy Technology Education Travel Canada Alberta Bc British Columbia Manitoba Ontario Quebec Nova Scotia Pei New Brunswick Newfoundland And Labrador Nunavut Northwest Territories Yukon Globe And Mail
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer's RSV vaccine shows benefit in immuno-compromised adults in studyA single 120 microgram dose of the vaccine generated strong neutralizing antibodies against both subtypes of RSV, called RSV-A and RSV-B, across all groups...
Read more »
Pfizer's RSV vaccine shows benefit in immuno-compromised adults in studyA single 120 microgram dose of the vaccine generated strong neutralizing antibodies against both subtypes of RSV, called RSV-A and RSV-B, across all groups...
Read more »
Ontario expanding access to RSV vaccines for young children, pregnant womenTORONTO — Ontario is doubling the number of children eligible for vaccination against a virus that can make young kids very sick.
Read more »
RSV vaccines available to young children, pregnant women in OntarioOntario is doubling the number of children eligible for vaccination against a virus that can make young kids very sick.
Read more »
Ontario expanding access to RSV vaccines for young children, pregnant womenOntario is doubling the number of children eligible for vaccination against a virus that can make young kids very sick.
Read more »
Ontario expanding access to RSV vaccines for young children, pregnant womenChief Medical Officer of Health Dr. Kieran Moore says the changes should better protect young children from severe outcomes
Read more »